Hilden, Germany, and Germantown, MD – November 16th, 2010 – Today QIAGEN launched the free QIAGEN App, an application that can be used on iPhone and iPad mobile devices with tables of commonly used lab buffers and solutions as well as a variety of conversion and dilution calculators, all aimed at easing scientists’ daily work.
QIAGEN App allows users to watch more than 20 video tutorials on the iPhone and iPad on innovative technologies in many application areas such as automation, gene expression analysis, genotyping and pyrosequencing. The iPad application will offer a bundle for QIAcube users that includes protocol sheets, support documents and updates.
QIAGEN App can be downloaded at www.qiagen.com/support/qiaapps/default.aspx or found in the Support - Tips & Tools section on www.qiagen.com and will be regularly updated and extended with other apps following soon.
iPhone and iPad are trademarks of Apple Inc. Use of these marks does not imply any endorsement by or affiliation with Apple.
For a high resolution image, please contact us at email@example.com.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make these isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The Company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the first FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs nearly 3,600 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.
Dr. Marc Egelhofer